The life sciences industry in Australia has called for better funding for the country’s medicine and technology regulator.
Trade group Medicines Australia is leading the calls for more money for the Therapeutic Goods Administration (TGA) after the agency flagged increases in costs this year due to unexpected issues such as the regulation of cannabis and nicotine vaping products.
"93% of the TGA’s revenue is collected through fees and charges"Elizabeth de Somer, chief executive of Medicines Australia, wants to see some recognition of these challenges in the upcoming Federal Budget.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze